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Cancer cells characteristically exhibit an elevated rate of gly-
colysis, even under aerobic conditions [1–3]. The increased de-
mand for glucose to fuel energy production in tumors translates 
to elevated expression and activity of cell surface glucose trans-
port proteins, which can be exploited for noninvasive imaging us-
ing glucose analogs. Early studies using [14C]deoxyglucose dem-
onstrated cellular uptake by glucose transporters (GLUTs)1 and 
phosphorylation for glycolytic processing [4, 5]. Because its struc-
ture precluded isomerization by the next enzyme in the pathway, 
subsequent metabolism was not possible, causing the partially 
processed, labeled analogue to accumulate in the cell. These find-
ings have been applied extensively in clinical imaging by positron 
emission tomography (PET) in which 18FDG (2-fluoro-2-deoxy-
glucose) uptake is used to visualize tumor activity and location. 
The method is sensitive and quantitative [4, 5]. For many high 
throughput preclinical studies, however, 18FDG is impractical due 
to the specialized instrumentation required and short half-life of 
the isotope. Therefore, alternatives to radionuclide labeled 2-deox-
yglucose (2-DG) would be valuable.
Fluorescent optical imaging is a rapidly expanding methodol-
ogy for noninvasive evaluation of disease and tumor progression, 
with application for drug and biomarker development [6–11]. Tar-
geted near-infrared (NIR) fluorophores have shown excellent sig-
nal-to-noise ratios in whole animals and images can be collected 
over longer periods than radioactively labeled probes. NIR fluoro-
phores emit between 650 and 900 nm, a range in which absorption 
coefficients of tissues are relatively low, and nonspecific fluores-
cence is minimized. By effectively reducing background, sensi-
tivity and depth of penetration are increased which is directly re-
flected in improved image quality [8, 12, 13].
Several groups have reported the use of fluorescent analogs 
for imaging 2-DG uptake in mice [14–17]. O’Neil et al. [16] and 
Lloyd et al. [15] demonstrated that 2-[N-(7-nitrobenz-2-oxa-1,3-di-
axol-4-yl)amino]-2-deoxyglucose (2-NBDG) could be taken up in 
cultured tumor cells via the glucose transporters. Accumulation 
of 2-NBDG in human breast cancer cells (MCF-7) and pig vascu-
lar smooth muscle cells was effectively blocked by the addition of 
d-glucose. Using fluorescence microscopy, a Cy5.5-d-glucosamine 
conjugate was shown to accumulate in a number of cell lines, but 
uptake could not be blocked by glucose, implying that the uptake 
mechanism was not dependent on specific glucose transporters. 
Furthermore, when used to image tumor xenografts, the tumor-
to-background ratio of Cy5.5-d-glucosamine was not significantly 
different from Cy5.5 alone [14]. Pyropheophorbide 2-deoxyglu-
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Abstract
Malignant neoplasms exhibit an elevated rate of glycolysis over normal cells. This characteristic can be exploited for optical imaging of 
tumors in mice. A near-infrared fluorophore, IRDye 800CW, emission maximum 794 nm, was conjugated to 2-deoxyglucose (2-DG). An 
immunofluorescent cell-based assay was used to evaluate specificity and sensitivity of the conjugate in cultured cell monolayers. Dose-
dependent uptake was established with increasing concentrations of IRDye 800CW 2-DG for epithelial and prostate carcinomas. IRDye 
800CW 2-DG was specifically blocked by an antibody against GLUT1 glucose transporter, and by excess unlabeled 2-DG or d-glucose. 
Signal was increased by a phorbol ester activator of glucose transport. Fluorescence microscopy data confirmed localization of the conju-
gate in the cytoplasm. Subsequent in vivo studies optimized dose, clearance, and timing for signal capture in nude mouse xenografts. In 
all cases, tumors were clearly imaged with good signal-to-noise characteristics. These data indicate that IRDye 800CW 2-DG is a broadly 
applicable optical imaging agent for in vivo imaging of neoplasms in mice.
Keywords: IRDye 800CW, 2-deoxyglucose, near infrared, molecular imaging, immunofluorescent assay, fluorescence microscopy, whole 
animal imaging
Abbreviations: 2-DG, 2-deoxyglucose; FBS, fetal bovine serum; 18FDG, 2-fluoro-2-deoxyglucose; GLUTs, glucose transporters; LUT, look-
up-table; 2-NBDG, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose; NIR, near infrared; PBS, phosphate-buffered saline; 
PET, positron emission tomography; ROI, regions of interest; SNR, signal-to-noise ratio.
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cosamide (excitation/emission of 667/679 nm), a potential agent 
for photodynamic therapy of human tumors, was implicated in 
GLUT targeting by d-glucose competition, and in this case, con-
focal microscopy was used to confirm internalization of the fluo-
rophore [17].
In this report, our goal was to develop an alternative fluo-
rescent analogue of 2-DG and test its tumor detection efficacy in 
mice. We describe here the synthesis and performance of 2-DG la-
beled with the NIR dye, IRDye 800CW. This dye has been shown 
to yield high signal-to-background ratios in prior animal imaging 
experiments [12] and has been successfully used in a number of 
in vivo tumor targeting studies [6, 18–20]. We tested binding and 
uptake of the IRDye 800CW 2-DG targeting agent in vitro and in 
mice using several diverse solid tumor cell types. The mechanism 
of uptake was investigated by dose response, competition assays, 
and pharmacological activation of glucose transport. Specific ac-
cumulation of IRDye 800CW 2-DG observed in this broad group 
of cell lines both microscopically and in tumor-bearing intact mice 
underscores its utility for preclinical cancer research and provides 
insight into its efficacy.
Materials and methods
Cell culture, reagents, and instrumentation
22Rv1 human prostate adenocarcinoma, A431 human epider-
moid carcinoma, and SW620 colorectal carcinoma cells were pur-
chased from American Type Culture Collection (ATCC; Manassas, 
VA) and maintained in RPMI 1640 containing 10% fetal bovine se-
rum (FBS; Hyclone, Logan, UT), DMEM containing 10% FBS, or Lei-
bovitz’s L-15 containing 10% FBS, respectively. PC3M-LN4 human 
prostate adenocarcinoma cells derived from PC3 were kindly pro-
vided by Dr. Isaiah J. Fidler (MD Anderson Cancer Center, Hous-
ton, TX) and maintained in minimal essential medium containing 
10% FBS, sodium pyruvate, and nonessential amino acids. Human 
breast cancer cell lines, MDA-MB-231 and SKBr3, and human glio-
blastoma cell line, U87MG, were purchased from ATCC. Human 
melanoma cell line, M21-L, was kindly provided by Dr. David A. 
Cheresh (Moores Cancer Center, University of California, San Di-
ego). The cells were cultured in DMEM supplemented with high 
glucose and F12 nutrient (DMEM/F12, Invitrogen, Carlsbad, CA) 
with 10% FBS. 3T3–L1 fibroblasts were purchased from ATCC and 
differentiated to adipocytes as previously published using dexa-
methasone, isobutyl-methylxanthine, and insulin [21].
PMA (phorbol-12-myristate-13-acetate) and 2-amino-2-deoxy-
d-glucose hydrochloride were purchased from Sigma-Aldrich (St. 
Louis, MO). GLUT1 monoclonal antibody was purchased from 
Abcam (Cambridge, MA). TO-PRO-3 was obtained from Molec-
ular Probes, Inc. (Eugene, OR). CellTracker CM-Dil and Sytox 
Green were purchased from Invitrogen. The Odyssey Infrared Im-
aging System, Aerius Automated Infrared Imaging System, and 
Pearl Imager were provided by LI-COR Biosciences (Lincoln, NE).
Synthesis of IRDye 800CW 2-DG
IRDye 800CW NHS ester (reactive dye; LI-COR Biosciences, 
Lincoln, NE) and 2-amino-2-deoxy-d-glucose hydrochloride were 
solubilized and reacted for 2 h at ambient temperature in 1 M po-
tassium phosphate buffer at pH 8.5. The dye conjugate was pu-
rified by HPLC, monitored at 260 and 780 nm, using a 10 × 250-
mm Inertsil (Varian, Walnut Creek, CA) semiprep column, 5 μm, 
ODS-3. This column was equilibrated and eluted at 2.7 mL/min 
(108 bar pressure) using a gradient with 20% acetonitrile:80% 
50 mM triethylammonium acetate (pH 5.6) to 30% acetonitrile:70% 
triethylammonium acetate in 40 min. The two resolved anomers 
of IRDye 800CW 2-DG were pooled. Samples were protected from 
light, dried overnight under vacuum, reconstituted in water, and 
applied to a cation-exchange column (Amberlite-IR120 Na+ Form, 
Sigma-Aldrich) equilibrated with water. The IRDye 800CW 2-
DG was eluted from the column with water and the concentra-
tion measured by spectroscopy. The eluted material was sterilized 
by passage through a 0.2-μm syringe filter into a sterile container. 
The IRDye 800CW 2-DG was aliquoted and lyophilized, and the 
purity was verified by NMR.
Cell-based assays
Binding and specificity of IRDye 800CW 2-DG were evaluated 
by immunofluorescent assay. Cells were grown to approximately 
90% confluency in a 96-well microtiter plate and starved for 2 h in 
serum-free low-glucose DMEM. Starvation media were replaced 
with media containing increasing concentrations of the IRDye 
800CW 2-DG (0–50 μM), increasing concentrations of unlabeled 2-
DG (0.8–375 mM) plus 5 μM IRDye 800CW 2-DG, or with increas-
ing concentrations of GLUT1 monoclonal antibody (0.4–100 μg/
mL) plus IRDye 800CW 2-DG (5 μM) and incubated at 37 °C for 
an additional hour. The assay was stopped by fixation with 4% 
formaldehyde solution for 20 min followed by four washes in 1X 
PBS + 0.02% Triton X-100 to remove unbound dye and permeabi-
lize the cells. The plates were blocked in Odyssey Blocking Buf-
fer (LI-COR Biosciences) for 1.5 h and incubated for an additional 
hour with TO-PRO-3 DNA stain (ex/em: 642/669 nm) diluted 
1:5000 for normalization of cell number. Washing steps were re-
peated with Odyssey Buffer + 0.02% Tween 20 and the plate was 
scanned with an Aerius Automated Infrared Imaging System. 
Quantification was normalized by ratiometric analysis of the fluo-
rescent intensities obtained from the 700- and 800-nm channels.
PMA induction of glucose uptake was performed by a modifi-
cation of the procedure described by Bosch et al. [22]. Briefly, 96-
well overnight cultures of fully differentiated 3T3–L1 adipocytes 
were incubated for 4 h at 37 °C with DMEM containing increasing 
concentrations of PMA (0–5 μM). IRDye 800CW 2-DG was added 
to a final concentration of 5 μM per well and incubation was con-
tinued for 15 min at 37 °C after which the reaction was terminated. 
Cells were fixed, permeabilized, blocked, stained with TO-PRO-3, 
and analyzed as described above.
Determination of 2-DG uptake by fluorescence microscopy
Serum-starved cultures of U87MG (not shown), SKBr3, MDA-
MB-231, M21-L, SW620, and A431 tumor cell lines were incu-
bated at 37 °C for 2 h with 50 μM IRDye 800CW 2-DG. Cells were 
washed twice with PBS and pelleted by centrifugation. Cell mem-
branes were specifically stained with 2 ng of CellTracker CM-Dil 
according to the manufacturer’s instructions. Cell nuclei were 
stained with 1 μM Sytox Green in 95% ethanol.
To determine the competitive effect of glucose, MDA-MB-231 
cells were incubated at 37 °C with DMEM plus 0, 12.5, 25, 50, and 
100 mM d-glucose for 3.5 h. IRDye 800CW 2-DG was added to a 
final concentration of 50 μM and cells were incubated at 37 °C for 
another 30 min. Cell membrane and nuclei were stained as de-
scribed above. Ten MDA-MB-231 cells incubated at each glucose 
concentration were randomly chosen for analysis. Cells were im-
aged by fluorescence microscopy using either a Leica DM6000b 
Bio/Med microscope (Leica Microsystems Inc., Bannockburn, IL) 
or a Zeiss Axio Observer (Carl Zeiss MicroImaging Inc., Thorn-
wood, NY) equipped with a xenon lamp and NIR filters (ex/
HQ760/40, em/HQ830/50; Chroma Technology Corp., Rocking-
ham, VT). Signals imaged separately for IRDye 800CW 2-DG (ex/
em 785/810 nm), cell membrane (ex/em 553/570 nm), and cell 
nuclei (ex/em 488/510 nm) were merged as presented in Figure 
2 and Figure 3.
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A notched box-and-whisker plot [23, 24] was used to analyze 
the distribution and statistical differences of the microscopy data. 
The plot provides the minimum, 25th percentile, median (central 
line), mean (+), 75th percentile, and maximum. The medians (cen-
tral lines) of two box-and whisker plots are significantly different 
at the 0.05 confidence level if the corresponding notches do not 
overlap. Statistical analysis was performed using SAS software 
version 9.1 (SAS Institute Inc., Cary, NC) for Microsoft Windows.
In vivo animal imaging and analysis
All animals used in the imaging experiments were cared for 
and maintained under the supervision and guidelines of the Uni-
versity of Nebraska–Lincoln Institutional Animal Care and Use 
Committee. Mice were maintained on a purified maintenance diet 
(AIN-93M) obtained from Harlan Teklad (Madison, WI). All mice 
were anesthetized with 2% isoflurane throughout all procedures. 
Male athymic nude (nu/nu) mice, obtained from Charles River Lab-
oratories, Inc. (Cambridge, MA) at 4 wks of age, were subcutane-
ously injected with a suspension of 106 cells in 100 μL serum-free 
medium specific to the cell type under analysis. For all imaging 
experiments, the fluorescent contrast agent was injected intrave-
nously through the tail vein. At the experimental endpoints, mice 
were sacrificed and images of the excised organs were obtained.
Images analyzed in a longitudinal series for each particular 
mouse were normalized using a look-up-table (LUT) with com-
mon minimum and maximum values. Signal-to-noise ratio (SNR) 
was calculated using the following formula: SNR = ((mean tumor 
intensity) – (mean background intensity))/standard deviation of 
mean background [25]. Regions of interest (ROI) for both tumor 
and background were derived from equivalent sized areas con-
taining the same number of pixels. ROIs were quantified for total 
pixel and mean pixel values.
Organ and tissue analyses
After final imaging, animals were sacrificed and organs sus-
pected of targeting agent accumulation (i.e., kidney, liver, stom-
ach, etc) were removed for imaging to confirm signal content. Or-
gans were snap-frozen in OCT compound for cryosectioning. 
Sections (8 μm thickness) were scanned in both the 700-nm chan-
nel for tissue autofluorescence and the 800-nm channel for the tar-
geted IRDye 800CW 2-DG fluorescence signal using the Odyssey 
Imaging System. The area-weighted fluorescence signal from the 
800-nm channel was used to compare targeting agent specificity.
Results
Characterization of IRDye 800CW 2-DG in cell binding assays
Binding specificity of IRDye 800CW 2-DG was evaluated on 
cultured A431, mouse 3T3–L1, and 22Rv1 cells in a microplate as-
say. A431 and 22Rv1 are human tumor cell lines with high and 
relatively lower metabolic rates, respectively. Differentiated 3T3–
L1 adipocytes were also evaluated, since they express basal lev-
els of glucose transport proteins that can be chemically increased. 
Confluent cell monolayers were incubated with increasing concen-
trations of the dye conjugate and relative NIR fluorescence inten-
sities were plotted. A dose-dependent increase in fluorescence oc-
curred for each of the three tumor cell types screened (Figure 1A). 
In a similar assay, serial dilutions (0–3 μM) of the unconjugated 
IRDye 800CW dye showed little or no increase in signal (data not 
shown). To examine the specificity of 2-DG targeting, A431 cells 
were preincubated with increasing concentrations of unlabeled 
2-DG (Figure 1B) or d-glucose (data not shown) prior to treat-
ment with IRDye 800CW 2-DG. The inhibition curves showed ex-
posure of the cells to ~40X excess unlabeled 2-DG prior to treat-
Figure 1. In-cell Western analysis demonstrates binding and competition on tumor cells in vitro. Following a brief starvation period, A431, 22Rv1, 
and 3T3–L1 cells were treated with increasing concentrations of IRDye 800CW 2-DG (0.1–50 μM) (A); unlabeled 2-DG (0.8–375 mM) plus IRDye 
800CW 2-DG (5 μM) (B); or GLUT1 monoclonal antibody (0.4–100 μg/mL) plus IRDye 800CW 2-DG (5 μM) (C). Differentiated 3T3–L1 adipocytes 
were treated with increasing concentrations of PMA (0.08–5 μM) for approximately 4 h. Following incubation, 5 μM IRDye 800CW 2-DG was 
added with an additional 15-min incubation at room temperature (D).
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ment with IRDye 800CW 2-DG almost completely eliminated 
fluorescence. Dependence of dye uptake on GLUT family trans-
porters was tested by the addition of the indicated quantities of 
anti-GLUT1 monoclonal antibody prior to incubation with IRDye 
800CW 2-DG (Figure 1C). Over 50% of fluorescence was blocked 
by ~25 μg/mL of the GLUT1 antibody. Finally, cellular recogni-
tion of 2-DG by GLUT family glucose transporters can be phar-
macologically increased by addition of the phorbol ester PMA to 
induce surface translocation from intracellular vesicles [22]. Dif-
ferentiated 3T3–L1 adipocytes were stimulated with increasing 
concentrations of PMA (0.08–5 μM) for 4 h prior to the addition of 
IRDye 800CW 2-DG. NIR fluorescence was increased by 50% with 
increasing PMA concentration (Figure 1D). Collectively, these re-
sults support specific recognition of IRDye 800CW 2-DG by tumor 
cells and adipocytes.
In vitro microscopic analysis
Microscopic examination of several additional tumor cell lines 
was undertaken to more precisely identify the cellular location of 
IRDye 800CW 2-DG. Cells were allowed to incubate first with the 
2-DG conjugate, followed by nuclear and cell membrane staining. 
Representative images are shown for a melanoma (M21-L) and 
two breast carcinoma cell lines (SkBr3 and MDA-MB-231). Fluo-
rescence microscopy revealed significant IRDye 800CW 2-DG sig-
nals in all tumor cell lines evaluated (Figure 2). Similar results 
were obtained for prostate tumor lines used in this study and for 
U87 glioma cells (data not shown). Inspection of merged images 
at low magnification illustrated homogeneous cytoplasmic loca-
tion of IRDye 800CW 2-DG with no nuclear or cell surface colocal-
ization (Figure 2, top two rows). Deconvolved epifluorescent im-
ages obtained at a higher magnification stained similarly showed 
no colocalization of the cytosolic 2-DG-labeled fluorophore with 
the nuclear signal and confirmed the intracellular location of the 
dye (Figure 2, bottom panels). To establish the specificity of IRDye 
800CW 2-DG uptake, we performed competitions by incubating 
MDA-MB-231 cells with increasing concentrations of d-glucose 
prior to the addition of the dye and collection of microscopic im-
ages (Figure 3A). Normalized fluorescence intensity of individual 
randomly selected cells was then quantified by confocal micros-
copy for each glucose concentration. Statistical analysis of these 
signals using the notched box-and-whisker plot [23, 24] showed 
that a significant decrease in IRDye 800CW 2-DG uptake occurred 
between 25 and 50 mM d-glucose addition (P < 0.05; Figure 3B).
In vivo characterization of IRDye 800CW 2-DG
Since many tissues have relatively high densities of glucose 
transporters, it was important to test the specificity of IRDye 
800CW 2-DG in mice by comparing its clearance profile to that of 
IRDye 800CW carboxylate (nonreactive form). Mice bearing sub-
cutaneous 22Rv1 xenografts were given an intravenous injection 
of 20 nmol IRDye 800CW 2-DG or IRDye 800CW carboxylate. Im-
ages were collected with the Pearl Imager at intervals between 18 
and 72 h postinjection. Signal intensities corrected for background 
revealed ~4-fold increase in tumor retention of IRDye 800CW 2-
DG compared to the carboxylate (Figure 4). Serial images an-
alyzed over the total 5-day period of the study showed that sig-
nal intensities peaked at ~24 h. This time point was selected for all 
subsequent animal imaging studies.
Figure 2. Microscopic analysis of intracellular fluorophore accumulation. Fluorescent images were collected on tumor cell lines (MDA-MB-231, 
M21-L, SKBr3, SW620, and A431 as indicated) following incubation with IRDye 800CW 2-DG (50 μM) in conjunction with a stain specific for cell 
nuclei (CN) or cell membrane (CM). Scale bar = 10 μm. IRDye 800CW 2-DG is presented in red with CN and CM colored in green.
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Next, we optimized the concentration of IRDye 800CW 2-DG 
for imaging subcutaneous 22Rv1 tumors. Tumor-bearing mice 
were injected intravenously with increasing concentrations of 
IRDye 800CW 2-DG and imaged 24 h postinjection (Figure 5). Tu-
mor SNR increased with increasing concentration of the labeled 
agent. Although tumors were visible regardless of dose, a range of 
10–20 nmol was identified as the effective working dose for sensi-
tive detection.
Early tumor detection was examined by a longitudinal analysis 
of mice bearing PC3M-LN4 prostate xenografts. Images were col-
lected weekly, 24 h after intravenous injection of IRDye 800CW 2-
DG (Figure 6A). SNR was again used as a parameter to evaluate 
time-dependent changes in tumor size (Figure 6B). A SNR of 3, the 
limit at which we were able to identify tumors with 95% accuracy, 
was achieved by week 1. This value increased to 11.7 by week 3 
and was saturated by week 5. This is consistent with our previ-
ous findings for orthotopic prostate tumors [25], in which the SNR 
reached a plateau, but the relative area covered by signal intensi-
ties of this magnitude was still increasing with tumor size.
Finally, multiple tumor models were challenged using the op-
timized probe conditions discussed above. Mice bearing ~0.5 cm 
subcutaneous tumors arising from 22Rv1, A431, and SW620 cells 
(Figure 7A–C, respectively) were injected intravenously with 
15 nmol IRDye 800CW 2-DG. Images were collected 24 h postin-
jection and analyzed for fluorescence. The intensity of the fluores-
cence, which presumably reflects uptake of the agent by the tu-
mors, varied depending on cellular origin.
Evaluation of fluorescence signal in organs, tissues, and tumors
Organ and tissue sections from animals receiving PBS, IRDye 
800CW carboxylate, or IRDye 800CW 2-DG were screened for re-
sidual signal. All specimens were cryopreserved, sectioned, and 
scanned in two channels on the Odyssey Imaging System for spe-
cific area-weighted fluorescence to autofluorescence. Specific sig-
nals for each organ or tissue were normalized to the PBS signal of 
that tissue, arbitrarily set to 1. Low levels of NIR signal were de-
tected in all organs evaluated for PBS and IRDye 800CW carboxyl-
ate treatments (Figure 8). However, IRDye 800CW 2-DG showed 
significant retention in the kidney, muscle, and liver, giving rise 
to signal intensities ~3- to 4-fold higher than the carboxylate. Re-
tention of either IRDye 800CW carboxylate or IRDye 800CW 2-DG 
Figure 3. Competitive binding captured with fluorescent microscopy. (A) Fluorescent images of MDA-MB-231 following incubation with increas-
ing concentrations of d-glucose (0–100 mM) and IRDye 800CW 2-DG (50 μM). Scale bar = 10 μm for the fluorescent images. (B) Fluorescence in-
tensity at each wavelength was quantified for 10 randomly selected individual cells at each d-glucose concentration indicated, and IRDye 800CW 
2-DG signal was normalized to the nuclear signal for each one. The notched box-and-whisker plot was used to illustrate the distributions and the 
statistical differences of the data. The plot provides the minimum, 25th percentile, median (central line), mean (+), 75th percentile, and maximum.
Figure 4. Pharmacokinetics of IRDye 800CW 2-DG clearance in mice. 
Male athymic nude mice bearing ~0.5-cm subcutaneous 22Rv1 tumors 
were injected via the tail vein with IRDye 800CW 2-DG (20 nmol; ■) or 
IRDye 800CW carboxylate (20 nmol; ●). Animals were imaged at 18, 
24, 30, 42, and 72 h post agent injection. Signal intensity per mm2 is the 
total signal intensity per area (mm2) of those pixels scored at greater 
than 3 standard deviations over background.
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was minimal for brain, heart, lung, intestine, and spleen/pancreas. 
Importantly, if specimens were harvested after 3 days, rather than 
24 h, from animals receiving IRDye 800CW 2-DG or IRDye 800CW 
carboxylate, all organs were minimally fluorescent, while tumors 
exhibited 83% signal increase for the 2-DG coupled dye over 
IRDye 800CW carboxylate (data not shown).
Inspection of the scanned tumor sections revealed heterogene-
ity in the localization of dye within both 22Rv1 and A431 tumors 
(Figure 9A and B, inset panels, respectively). Areas of intense fluo-
rescence corresponded to histologically viable regions of the tumor, 
and were notably absent from the periphery. Thus, the most signif-
icant sources of nonspecific fluorescence correspond predictably to 
tissues that exhibit relatively high glucose uptake rates, which is 
consistent with the expected targeting pattern of 2-DG, and signifi-
cant specific tumor fluorescence is associated with living tissue that 
is relatively remote from the well-vascularized tumor surface. Col-
lectively, these data support the use of IRDye 800CW 2-DG to probe 
metabolic glucose uptake potential of tumors in mice.
Discussion
Cancer cells are known to exhibit enhanced glucose utilization 
to sustain their increased energy demands under oxygen-deficient 
growth conditions. We exploited the increased glucose metabo-
lism in tumor cells for noninvasive imaging in intact mice by de-
veloping the NIR fluorescent glucose analogue, IRDye 800CW 2-
DG. Multiple tumor cell lines were examined in vitro and in vivo 
for accumulation of IRDye 800CW 2-DG. Tumor cells and 3T3–L1 
adipocytes bound the probe effectively in vitro in a dose-depen-
dent fashion. In addition, fluorescence microscopy confirmed that 
IRDye 800CW 2-DG was present in the cytoplasm of all tumor cell 
lines examined. Binding could be blocked by unlabeled 2-DG and 
stimulated by the phorbol ester, PMA; IRDye 800CW 2-DG up-
take was also effectively blocked by excess d-glucose or antibodies 
against the glucose transport protein GLUT1. In vivo, the IRDye 
800CW 2-DG probe was >4-fold more effective in detection and 
monitoring multiple tumor types than the unlabeled fluorophore, 
and was found to localize in viable but relatively poorly vascular-
ized regions of the tumors. Collectively, these results demonstrate 
specificity of IRDye 800CW 2-DG and suggest involvement of the 
GLUT family of transporters in its uptake.
It has been shown that specific GLUT family proteins are in-
volved in accelerated glucose uptake in tumors. GLUT1, in partic-
ular, has been shown to be an important player in several stages of 
cancer progression (reviewed in [27–30]). Evidence for its specific 
involvement in accumulation of FDG has been provided by PET 
imaging in animal models of prostate and mammary carcinoma, 
in which the rate of uptake was directly correlated to levels of 
GLUT1 protein expression in the tumors [28, 29]. Previous reports 
have also examined total expression or cell surface presentation of 
GLUT1 in human tumor cell lines. In one study, GLUT1 mRNA 
levels were found to be higher in A431 tumor cells than in other 
cells lines tested [31]. GLUT1 transporters have also been found 
to decrease cell surface expression by as much as 75% when 3T3–
L1 fibroblasts were differentiated [32] relative to undifferentiated 
cells. Our in vitro results are consistent with these studies since 
A431 cells exhibited higher binding to IRDye 800CW 2-DG com-
pared to unstimulated 3T3–L1 adipocytes, suggesting that GLUT1 
mediates binding of the optical agent. This was further supported 
by successful use of PMA, a potent activator of the PKC (protein 
kinase C) family known to increase the rate of glucose uptake [22, 
33, 34] primarily by increasing GLUT1 at the plasma membrane 
[22], to stimulate uptake of IRDye 800CW 2-DG. It should be noted 
that GLUT4 (insulin-sensitive isoform) has also been reported to 
increase on PMA stimulation [32, 35, 36], so it is possible that both 
are involved in the uptake of IRDye 800CW 2-DG.
Previous studies using fluorophore-labeled 2-DG as a target-
ing agent for noninvasive optical tumor imaging in mice have re-
Figure 5. Determination of optimal fluorophore dose for noninvasive tumor imaging. Prostate tumor xenografts (22Rv1) were implanted in four 
athymic nude mice. Each animal received one of the following doses intravenously via the tail vein: (A) 2.5 nmol, (B) 5.0 nmol, (C) 10 nmol, or (D) 
20 nmol. Images were taken 24 h postinjection and normalized to the same LUT (0–10,000).
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ported various outcomes in vivo following positive binding assays 
in vitro. For example, tumor and normal tissue uptake between 
Cy5.5–2-DG and Cy5.5–NHS in mice was not significantly differ-
ent [14]. In contrast, we observed that the tumor-to-background 
ratio of IRDye 800CW 2-DG was 4-fold greater than that of IRDye 
800CW carboxylate, indicating that the tumor signal was primar-
ily the result of specific cellular uptake of the agent.
Although Cy5.5 has been used successfully in animal imaging 
studies, inherent characteristics of this dye, such as nonspecific 
binding by the dye and autofluorescence at the emission wave-
length, have been shown to decrease signal-to-background, com-
promising the results [13, 37]. This was demonstrated by a side-
by-side comparison between Cy5.5 EGF and IRDye 800CW EGF in 
which the latter targeting agent yielded a significantly higher tu-
mor-to-background ratio [37]. This result was attributed to a com-
bination of Cy5.5 nonspecific dye binding and autofluorescence at 
the emission wavelength.
Analysis of organ sections showed an increased retention of 
IRDye 800CW 2-DG over IRDye 800CW carboxylate in the kidney, 
muscle, and liver. The kidney signal is indicative of probe clearance, 
while muscle and liver would be expected to show increased sig-
nal levels compared to lung, spleen, and heart due to an increased 
density of GLUT receptors in these tissues. Intestine, though a site 
of extensive glucose absorption, utilizes a secondary active trans-
port mechanism for glucose uptake that is dependent on a GLUT 
isoform not as readily recycled between the cell surface and the in-
tracellular compartments as GLUT1 and GLUT4. This observation 
supports a mechanism for fluorophore uptake, as discussed below, 
that does not involve conventional transport. It is reasonable for 
the tumors to exhibit further increases in signal in vivo, since hy-
poxia has been shown to elevate GLUT1 expression in human tu-
mor tissue sections and in human tumor cell lines cultured under 
low oxygen conditions [33]. In particular, studies have shown that 
GLUT1 expression correlated with viable but extremely hypoxic 
tissue surrounding necrotic regions in tumors, and PET imaging 
of these regions confirmed that both hypoxia and GLUT1 expres-
sion correlated with increased FDG uptake. This is consistent with 
our analysis of tumor sections in which areas of high signal inten-
sity surround the necrotic center and occur only beneath the vascu-
lar, presumably better oxygenated, tumor surface. Thus, analysis of 
IRDye 800CW 2-DG fluorescence has the potential to predict GLUT 
expression and hypoxia within tissue.
The molecular mechanism by which IRDye 800CW 2-DG en-
ters the cell via the GLUT transporters is unknown. Fluorophore-
labeled 2-DG has a molecular mass of ~ 1330 Da and is estimated 
to occupy a dimension of 18–23 Å, whereas 2-DG (MW = 164 Da) 
has a reported diameter of ~5.8 Å. Salas-Burgos et al. [38] pre-
dicted a three-dimensional model for GLUT1 with a 15 × 8 Å 
channel connecting the extracellular and intracellular binding do-
mains. The GLUT transporters are highly homologous to lactose 
permeases, which have been shown to move monosaccharide sug-
ars across membranes as a result of conformational changes ini-
tiated by the specific binding energies [39]. The transporter sam-
ples two alternative states in response to sugar binding, with the 
substrate docking site either facing intracellularly or extracellu-
larly [38, 40]. Since the size of IRDye 800CW 2-DG is about three 
Figure 6. Longitudinal imaging of tumor growth with IRDye 800CW 2-DG. Male athymic nude mice injected subcutaneously with PC3M-LN4 
cells were given weekly tail vein injections of IRDye 800CW 2-DG (15 nmol) and monitored by imaging weekly 24 h after delivery of the optical 
agent (A). SNR were calculated for the weekly images normalized to the same LUT (B).
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Figure 7. Detection of multiple diverse tumor types by noninvasive 
imaging of IRDye 800CW 2-DG. Athymic nude mice bearing (A) sub-
cutaneous prostate (22Rv1), (B) epidermoid (A431), and (C) colorec-
tal (SW620) carcinomas received 15 nmol IRDye 800CW 2-DG intra-
venously via the tail vein. Images were acquired 24 h postinjection. 
Fluorescent 800-nm signals were presented in pseudo color and over-
laid on the white light image for each animal model. High signal in-
tensities register as red while low signal is illustrated as blue.
Figure 8. Tissue section analyses. Tumor bearing athymic nude mice 
were injected with PBS, IRDye 800CW carboxylate, or IRDye 800CW 
2-DG as indicated. Animals were sacrificed after imaging and tissues 
and organs were cryopreserved in OCT compound. Three to four fro-
zen 8-μm sections per organ were scanned on the Odyssey Imaging 
System and signals were averaged. Relative fluorescence was deter-
mined by normalizing respective tissues to PBS.
Figure 9. Distribution of IRDye 800CW 2-DG 
within tumor sections. Athymic nude mice 
bearing 22Rv1 (A) or A431 (B) tumors were 
injected via the tail vein with 10 or 14 nmol 
of IRDye 800CW 2-DG, respectively, and im-
aged 24 h postinjection. Excised tumors were 
fixed, paraffin-embedded, sectioned, and 
scanned on the Odyssey Imaging System. 
Specific fluorescence in the 800-nm channel 
is in green and autofluorescence in the 700-
nm channel is in red (inset panels).
times larger than the endogenous ligand, it is unlikely that GLUT1 
passes the fluorophore-tagged 2-DG through its intramembrane 
channel, despite considerable predicted flexibility within the bind-
ing and transport domain. The conjugated ring system that gives 
rise to the fluorescence properties of the dye is not entirely dissim-
ilar to the structures of GLUT inhibitors such as phloretin, which 
bind at the glucose binding site but are not able to be transported 
through the channel. Nonetheless, the data implicate GLUT pro-
teins in the movement of IRDye 800CW 2-DG into the cell. We 
suggest this is probably due to endocytosis of the GLUT1/IRDye 
800CW 2-DG complexes.
In summary, we have characterized a general tumor targeting 
agent for noninvasive NIR optical imaging in mice. Because IRDye 
800CW 2-DG uptake is mediated by GLUT family proteins, this 
compound can be considered a metabolic optical agent with broad 
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applicability in preclinical testing for drug development, and in 
evaluation of mouse cancer models. This is the first report to inte-
grate data that not only demonstrate binding and uptake specific-
ity of a highly sensitive NIR fluorescent glucose analogue in vitro 
but also implicate the glucose transporter GLUT1 in the mecha-
nisms of enhanced detection in vitro and in vivo.
References
[1] J. G. Rajendran, D. A. Mankoff, F. O’Sullivan, L. M. Peterson, D. L. 
Schwartz, E. U. Conrad, A. M. Spence, M. Muzi, D. G. Farwell and 
K. A. Krohn, Hypoxia and glucose metabolism in malignant tumors: 
Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose 
positron emission tomography imaging, Clin. Cancer Res. 10 (2004), 
pp. 2245–2252. 
[2] O. Warburg, On the origin of cancer cells, Science 123 (1956), pp. 
309–314. 
[3] S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. Silverman, R. E. Coleman 
and M. E. Phelps, A tabulated summary of the FDG PET literature, J. 
Nucl. Med. 42 (2001), pp. 1S–93S. 
[4] K. C. Schmidt, G. Lucignani and L. Sokoloff, Fluorine-18-fluorodeoxy-
glucose PET to determine regional cerebral glucose utilization: A re-
examination, J. Nucl. Med. 37 (1996), pp. 394–399. 
[5] L. Sokoloff, M. Reivich, C. Kennedy, M. H. Des Rosiers, C. S. Patlak, K. 
D. Pettigrew, O. Sakurada and M. Shinohara, The [14C]deoxyglucose 
method for the measurement of local cerebral glucose utilization: The-
ory, procedure, and normal values in the conscious and anesthetized 
albino rat, J. Neurochem. 28 (1977), pp. 897–916. 
[6] J. L. Kovar, M. A. Simpson, A. Schutz-Geschwender and D. M. Olive, 
A systematic approach to the development of fluorescent contrast 
agents for optical imaging of mouse cancer models, Anal. Biochem. 367 
(2007), pp. 1–12. 
[7] J. V. Frangioni, In vivo near-infrared fluorescence imaging, Curr. Opin. 
Chem. Biol. 7 (2003), pp. 626–634. 
[8] M. Gurfinkel, S. Ke, X. Wen, C. Li and E. M. Sevick-Muraca, Near-in-
frared fluorescence optical imaging and tomography, Dis. Markers 19 
(2003), pp. 107–121. 
[9] H. Li, J. Chen, M. Zhang, Z. Zhang, D. Benaron, B. Chance, J. D. Glick-
son and G. Zheng, NIR optical probes targeting glucose transporters. 
In: A. P. Savitsky, Editor, Proceedings of SPIE, SPIE, Bellingham, WA 
(2004), pp. 254–261. 
[10] K. Licha, B. Riefke, B. Ebert and C. Grotzinger, Cyanine dyes as con-
trast agents in biomedical optical imaging, Acad. Radiol. 9 (Suppl. 2) 
(2002), pp. S320–S322. 
[11] B. J. Tromberg, N. Shah, R. Lanning, A. Cerussi, J. Espinoza, T. Pham, 
L. Svaasand and J. Butler, Non-invasive in vivo characterization 
of breast tumors using photon migration spectroscopy, Neoplasia 2 
(2000), pp. 26–40. 
[12] B. Chance, Optical method, Annu. Rev. Biophys. Biophys. Chem. 20 
(1991), pp. 1–28. 
[13] F. F. Jobsis, Noninvasive, infrared monitoring of cerebral and myocar-
dial oxygen sufficiency and circulatory parameters, Science 198 (1977), 
pp. 1264–1267. 
[14] Z. Cheng, J. Levi, Z. Xiong, O. Gheysens, S. Keren, X. Chen and S. S. 
Gambhir, Near-infrared fluorescent deoxyglucose analogue for tu-
mor optical imaging in cell culture and living mice, Bioconj. Chem. 17 
(2006), pp. 662–669. 
[15] P. G. Lloyd, C. D. Hardin and M. Sturek, Examining glucose transport 
in single vascular smooth muscle cells with a fluorescent glucose ana-
log, Physiol. Res. 48 (1999), pp. 401–410. 
[16] R. G. O’Neil, L. Wu and N. Mullani, Uptake of a fluorescent deoxyglu-
cose analog (2-NBDG) in tumor cells, Mol. Imaging Biol. 7 (2005), pp. 
388–392. 
[17] M. Zhang, Z. Zhang, D. Blessington, H. Li, T. M. Busch, V. Madrak, 
J. Miles, B. Chance, J. D. Glickson and G. Zheng, Pyropheophorbide 
2-deoxyglucosamide: A new photosensitizer targeting glucose trans-
porters, Bioconj. Chem. 14 (2003), pp. 709–714. 
[18] D. J. Hawrysz and E. M. Sevick-Muraca, Developments toward diag-
nostic breast cancer imaging using near-infrared optical measure-
ments and fluorescent contrast agents, Neoplasia 2 (2000), pp. 388–417. 
[19] D. Knapp, L. Adams, A. DeGrand, J. Niles, J. Ramos-Vara, A. Weil, 
M. O’Donnell, M. Lucroy and J. Frangioni, Sentinel lymph node map-
ping of invasive urinary bladder cancer in animal models using invis-
ible light, Eur. Urol. 178 (2007), pp. 2197–2202. 
[20] L. Sampath, S. Kwon, S. Ke, W. Wang, R. Schiff, M. E. Mawad and E. 
M. Sevick-Muraca, Dual-labeled trastuzumab-based imaging agent 
for the detection of human epidermal growth factor receptor 2 over-
expression in breast cancer, J. Nucl. Med. 48 (2007), pp. 1501–1510. 
[21] J. S. Moyers, P. J. Bilan, C. Reynet and C. R. Kahn, Overexpression of 
Rad inhibits glucose uptake in cultured muscle and fat cells, J. Biol. 
Chem. 271 (1996), pp. 23111–23116. 
[22] R. R. Bosch, M. Bazuine, M. M. Wake, P. N. Span, A. J. Olthaar, A. Sch-
urmann, J. A. Maassen, A. R. Hermus, P. H. Willems and C. G. Sweep, 
Inhibition of protein kinase CbetaII increases glucose uptake in 3T3–
L1 adipocytes through elevated expression of glucose transporter 1 at 
the plasma membrane, Mol. Endocrinol. 17 (2003), pp. 1230–1239. 
[23] R. McGill, J. W. Tukey and W. A. Larsen, Variations of box plots, Am. 
Statist. 32 (1978), pp. 12–16. 
[24] S. Salmond, Taking the mystery out of research: Box and whisker 
plots. Displaying mean, interquartile range, and range, Orthop. Nurs. 
26 (2007), p. 33. 
[25] J. L. Kovar, M. A. Johnson, W. M. Volcheck, J. Chen and M. A. Simp-
son, Hyaluronidase expression induces prostate tumor metastasis in 
an orthotopic mouse model, Am. J. Pathol. 169 (2006), pp. 1415–1426. 
[27] M. L. Macheda, S. Rogers and J. D. Best, Molecular and cellular regula-
tion of glucose transporter (GLUT) proteins in cancer, J. Cell. Physiol. 
202 (2005), pp. 654–662. 
[28] R. S. Brown, J. Y. Leung, S. J. Fisher, K. A. Frey, S. P. Ethier and R. L. 
Wahl, Intratumoral distribution of tritiated-FDG in breast carcinoma: 
Correlation between Glut-1 expression and FDG uptake, J. Nucl. Med. 
37 (1996), pp. 1042–1047. 
[29] A. C. Clavo, R. S. Brown and R. L. Wahl, Fluorodeoxyglucose uptake 
in human cancer cell lines is increased by hypoxia, J. Nucl. Med. 36 
(1995), pp. 1625–1632. 
[30] U. Haberkorn, I. Morr, F. Oberdorfer, M. E. Bellemann, J. Blatter, A. 
Altmann, B. Kahn and G. van Kaick, Fluorodeoxyglucose uptake in 
vitro: Aspects of method and effects of treatment with gemcitabine, J. 
Nucl. Med. 35 (1994), pp. 1842–1850. 
[31] L. Aloj, C. Caraco, E. Jagoda, W. C. Eckelman and R. D. Neumann, 
Glut-1 and hexokinase expression: relationship with 2-fluoro-2-de-
oxy-d-glucose uptake in A431 and T47D cells in culture, Cancer Res. 
59 (1999), pp. 4709–4714. 
[32] J. Yang, A. E. Clark, I. J. Kozka, S. W. Cushman and G. D. Holman, De-
velopment of an intracellular pool of glucose transporters in 3T3–L1 
cells, J. Biol. Chem. 267 (1992), pp. 10393–10399. 
[33] E. M. Gibbs, D. M. Calderhead, G. D. Holman and G. W. Gould, Phor-
bol ester only partially mimics the effects of insulin on glucose trans-
port and glucose-transporter distribution in 3T3–L1 adipocytes, Bio-
chem. J. 275 (Pt 1) (1991), pp. 145–150. 
[34] B. T. Nave, K. Siddle and P. R. Shepherd, Phorbol esters stimulate 
phosphatidylinositol 3,4,5-trisphosphate production in 3T3–L1 adipo-
cytes: Implications for stimulation of glucose transport, Biochem. J. 318 
(Pt 1) (1996), pp. 203–205. 
[35] G. D. Holman, I. J. Kozka, A. E. Clark, C. J. Flower, J. Saltis, A. D. Hab-
berfield, I. A. Simpson and S. W. Cushman, Cell surface labeling of 
glucose transporter isoform GLUT4 by bis-mannose photolabel. Cor-
relation with stimulation of glucose transport in rat adipose cells by 
insulin and phorbol ester, J. Biol. Chem. 265 (1990), pp. 18172–18179. 
[36] J. Yang, A. E. Clark, R. Harrison, I. J. Kozka and G. D. Holman, Traf-
ficking of glucose transporters in 3T3–L1 cells. Inhibition of traffick-
ing by phenylarsine oxide implicates a slow dissociation of transport-
ers from trafficking proteins, Biochem. J. 281 (Pt 3) (1992), pp. 809–817. 
[37] K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. 
Mawad, M. A. Barry and E. M. Sevick-Muraca, Comparison of visible 
and near-infrared wavelength-excitable fluorescent dyes for molecu-
lar imaging of cancer, J. Biomed. Opt. 12 (2007), p. 024017. 
[38] A. Salas-Burgos, P. Iserovich, F. Zuniga, J. C. Vera and J. Fischbarg, 
Predicting the three-dimensional structure of the human facilitative 
glucose transporter glut1 by a novel evolutionary homology strat-
egy: Insights on the molecular mechanism of substrate migration, 
and binding sites for glucose and inhibitory molecules, Biophys. J. 87 
(2004), pp. 2990–2999. 
[39] I. Smirnova, V. Kasho, J. Y. Choe, C. Altenbach, W. L. Hubbell and H. 
R. Kaback, Sugar binding induces an outward facing conformation of 
LacY, Proc. Natl. Acad. Sci. USA 104 (2007), pp. 16504–16509. 
[40] A. Carruthers, Facilitated diffusion of glucose, Physiol. Rev. 70 (1990), 
pp. 1135–1176. 
